Search research articles
Contact Us
Filters
Showing results (391-400 of 464) with videos related to
Page
of 47
Sort By:
The Lancet. Gastroenterology & Hepatology
|
July 24, 2025
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
Silvio Danese, Jessica R Allegretti, Stefan Schreiber, et al.
Journal of Crohn'S & Colitis
|
May 10, 2015
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]
Simon P L Travis, Dan Schnell, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial
Silvio Danese, Martina Goetsch, Laurent Peyrin-Biroulet, et al.
Gastroenterology
|
July 30, 2013
Reliability and initial validation of the ulcerative colitis endoscopic index of severity
Simon P L Travis, Dan Schnell, Piotr Krzeski, et al.
Gut
|
October 15, 2011
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
Simon P L Travis, Dan Schnell, Piotr Krzeski, et al.
Alimentary Pharmacology & Therapeutics
|
September 27, 2020
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study
Robert Battat, Niels Vande Casteele, Rish K Pai, et al.
Gastroenterology
|
February 8, 2022
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
William J Sandborn, Geert R D'Haens, Walter Reinisch, et al.
Journal of Crohn'S & Colitis
|
June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Lancet (London, England)
|
April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G Feagan, William J Sandborn, Geert D'Haens, et al.
Inflammatory Bowel Diseases
|
October 31, 2019
Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease
Saleh Al Draiweesh, Christopher Ma, Maan Alkhattabi, et al.
Page
of 47
Search research articles
Search
Showing results (391-400 of 464) with videos related to
Sort By:
Page
of 47
The Lancet. Gastroenterology & Hepatology
|
July 24, 2025
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
Silvio Danese, Jessica R Allegretti, Stefan Schreiber, et al.
Journal of Crohn'S & Colitis
|
May 10, 2015
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]
Simon P L Travis, Dan Schnell, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial
Silvio Danese, Martina Goetsch, Laurent Peyrin-Biroulet, et al.
Gastroenterology
|
July 30, 2013
Reliability and initial validation of the ulcerative colitis endoscopic index of severity
Simon P L Travis, Dan Schnell, Piotr Krzeski, et al.
Gut
|
October 15, 2011
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
Simon P L Travis, Dan Schnell, Piotr Krzeski, et al.
Alimentary Pharmacology & Therapeutics
|
September 27, 2020
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study
Robert Battat, Niels Vande Casteele, Rish K Pai, et al.
Gastroenterology
|
February 8, 2022
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
William J Sandborn, Geert R D'Haens, Walter Reinisch, et al.
Journal of Crohn'S & Colitis
|
June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Lancet (London, England)
|
April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G Feagan, William J Sandborn, Geert D'Haens, et al.
Inflammatory Bowel Diseases
|
October 31, 2019
Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease
Saleh Al Draiweesh, Christopher Ma, Maan Alkhattabi, et al.
Page
of 47